Research involving BPC-157 has focused primarily on VEGFR2, FAK, ERK1/2, eNOS, and extracellular matrix-associated pathways, whereas TB-500 investigations emphasize actin dynamics, cytoskeletal organization, cell migration, and tissue remodeling mechanisms
The oral bioavailability and safety of the BPC-157 peptide are subjects of ongoing research and debate due to its susceptibility to enzymatic degradation in the gastrointestinal tract
It was developed as a pharmaceutical drug and one small clinical trial was filed but it was canceled
Multiple studies have demonstrated an inverse correlation between SHBG and inflammatory markers, including the C-reactive protein (CRP), IL-6, and TNF-, suggesting that chronic low-grade inflammation may suppress hepatic SHBG synthesis